Objective Skeletal muscle is the most abundant human tissue and contains mainly post-mitotic nuclei. It also expresses the largest gene known in nature – dystrophin – whose mutations cause Duchenne muscular dystrophy, the most frequent and incurable childhood muscle disorder. These characteristics create hurdles that negatively impact on the development of therapies for muscle diseases, ranging from acute tissue loss to chronic neuromuscular disorders. Moreover, a lack of humanised models of muscle regeneration delays the understanding of its regenerative dynamics.My work has pioneered the use of human induced pluripotent stem (iPS) cells to generate genetically corrected myogenic cells for the autologous cell therapy of muscular dystrophies. Here I propose to exploit this technology together with biocompatible materials to develop three dimensional, iPS cell-derived, patient-specific artificial muscles. These bioengineered skeletal muscles will provide a model to study human muscle regeneration and a platform for tissue engineering and therapy development for severe muscle diseases.The project will be developed in two phases. First we will develop the iPS cell-derived muscle in vitro, introducing cell types and stimuli necessary to obtain a functional tissue. In the second phase we will exploit the muscle “organoids” for regenerative medicine and drug development. Specifically, we will investigate the artificial muscle potential for tissue replacement in vivo and then model different muscular dystrophies in vitro to screen drugs with therapeutic relevance. Finally, we will combine the tools and knowledge developed in the two aforementioned areas into a novel platform to optimise skeletal muscle gene and cell therapies. This project will bring together tissue engineering, drug development and cell therapy under the same translational technology, advancing the understanding of pathogenesis and the development of therapies for muscle diseases. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesmedical biotechnologytissue engineeringmedical and health sciencesbasic medicineneurologymuscular dystrophiesduchenne muscular dystrophynatural sciencesbiological sciencesgeneticsmutationmedical and health sciencesmedical biotechnologycells technologies Keywords Disease modeling and tissue engineering Programme(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Topic(s) ERC-2017-STG - ERC Starting Grant Call for proposal ERC-2017-STG See other projects for this call Funding Scheme ERC-STG - Starting Grant Host institution UNIVERSITY COLLEGE LONDON Net EU contribution € 1 089 738,00 Address GOWER STREET WC1E 6BT London United Kingdom See on map Region London Inner London — West Camden and City of London Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 1 499 738,00 Beneficiaries (2) Sort alphabetically Sort by Net EU contribution Expand all Collapse all UNIVERSITY COLLEGE LONDON United Kingdom Net EU contribution € 1 089 738,00 Address GOWER STREET WC1E 6BT London See on map Region London Inner London — West Camden and City of London Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 1 499 738,00 Third-party Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure. THE FRANCIS CRICK INSTITUTE LIMITED United Kingdom Net EU contribution € 410 000,00 Address 1 MIDLAND ROAD NW1 1AT London See on map Region London Inner London — West Camden and City of London Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 410 000,00
